<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">Recently, dornase alfa as a recombinant human deoxyribonuclease I is considered for clinical trials of patients with severe COVID-19 who mostly progress to an ARDS condition: hypoxemic respiratory failure associated with neutrophilia and neutrophil infiltration in the lungs, thick mucus in bronchi, and bronchiectasis (
 <xref rid="bib45" ref-type="bibr">Pottecher etÂ al., 2020</xref>). Dornase alfa acts as a mucolytic by cleaving extracellular chromosomal DNA from neutrophil extracellular traps. Accordingly, using this treatment for patients with ARDS in severe COVID-19 may lead to mucous plug clearance and accelerated recovery.
</p>
